Agile Therapeutics, Inc. provided revenue guidance for the Full Year ended December 31, 2023. For the year, the company expects net revenue to be in the range of $20 million to $21 million compared to $10.9 million for the full year 2022, representing an increase of 84% to 93%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4297 USD | +7.42% | +16.14% | -77.96% |
Mar. 28 | Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
Mar. 28 | Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M | MT |
1st Jan change | Capi. | |
---|---|---|
-77.96% | 2.74M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023